Is NVCT or NVO more undervalued in 2026?

CirclFi compares Nuvectis Pharma, Inc. (NVCT) and Novo Nordisk A/S (NVO) using 13 institutional-grade valuation models. NVCT has a Quality of Company score of 3.8/10 while NVO scores 10.0/10.

Which is a better buy — NVCT or NVO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NVCT and NVO valuations compare?

NVCT at $9.75 and NVO at $45.58 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NVCT vs NVO Valuation Comparison 2026 — Intrinsic Value Analysis

NVCT

Pharmaceutical Preparations

Nuvectis Pharma, Inc.

Quality

3.8

out of 10

Value Trap

SAFE

Price

$9.75

Last close

Models

6/13

Active

NVO

Pharmaceutical Preparations

Novo Nordisk A/S

Quality

10.0

out of 10

Value Trap

SAFE

Price

$45.58

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	NVCT Fair Value	NVCT Upside	NVO Fair Value	NVO Upside
Bayesian DCF	Intrinsic	$3.41	-65.0%	$31.49	-30.9%
Earnings Power Value	Intrinsic	—	—	$44.06	-3.3%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.15	-88.2%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVCT vs NVO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVCT vs NVO — Which Stock Is More Undervalued?

NVO scores higher with a 10.0/10 quality rating vs NVCT's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Nuvectis Pharma, Inc. (NVCT) and Novo Nordisk A/S (NVO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVCT currently trades at $9.75 with a QOC of 3.8/10, while NVO trades at $45.58 with a QOC of 10.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).